Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hypertension
- Sponsor
- NYU Langone Health
- Enrollment
- 81
- Locations
- 1
- Primary Endpoint
- Feasibility measured by the number of weekly sessions attended
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this study is to adapt and then evaluate the feasibility, acceptability, and efficacy of a telephone-based intervention (UPLIFT: Using Practice and Learning to Increase Favorable Thoughts) for individuals with elevated depressive symptoms and hypertension. UPLIFT is a group-based intervention that is delivered over 8 weekly sessions for 1 hour/week by phone.
Aim 1 of this study is to adapt UPLIFT using qualitative focus groups and individual interviews and to test the adapted UPLIFT program in a single-arm design. Aim 2 of this study is a randomized controlled trial (RCT) that will compare the effects of the adapted UPLIFT program to usual care (UC) and to test mediators and moderators of the effects of UPLIFT.
Detailed Description
Once 16 participants are enrolled (to form 2 groups of 8 patients each), an independent study staff member will determine participants' group assignments. The randomization sequence will be created a priori by Dr. Keith Goldfeld (biostatistician) by using a computer-generated list of random numbers with stratification by antidepressant medication use and baseline levels of depressive symptoms (PHQ scores \<10 and ≥10). UPLIFT: Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment. Usual care: Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of hypertension based on the criteria in the ICD-9/-10
- •Mild to moderate depressive symptoms (PHQ-9 ≥ 5)
- •English-speaking
- •If taking depression medications, medications must stable for the past 6 weeks (no change to type or dose)
- •Willing to provide informed consent, be audio-recorded, and comply with all other aspects of protocol
Exclusion Criteria
- •Moderate to severe depressive symptoms (PHQ-9 ≥ 15)
- •Current substance abuse
- •Current eating disorder
- •Self-harm within the past 3 months
- •Current obsessive-compulsive disorder
- •Current anxiety disorder (e.g., PTSD, panic disorder)
- •Active suicidal ideation
- •History of or current diagnosis of psychosis
- •Significant cognitive impairment (mini mental state examination score ≤ 20)
- •History of previous training in mindfulness
Outcomes
Primary Outcomes
Feasibility measured by the number of weekly sessions attended
Time Frame: 6 Months
Determined by the number of weekly sessions attended and number of days of home-based practice completed each week
Acceptability
Time Frame: 6 Months
8-item Client Satisfaction Questionnaire (CSQ-8)
Quick Inventory of Depressive Symptomatology (QIDS-SR 16)
Time Frame: 6 Months
Standardized depression instrument that has treatment sensitivity advantages over the PHQ-9 and will be administered at pre- and post-treatment. Total scores on the QIDS-SR16 range from 0 to 27 and reflect depression severity across 9 domains of the DSM-IV MDD criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes.
PHQ-9
Time Frame: 6 Months
validated measure of depressive symptoms. Items rate symptom severity during the prior 2 weeks based on DSM-IV diagnostic criteria for major depression. Scores range from 0-27; scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively. The PHQ-9 will be completed at screening and at all study visits (continuous scores).